ELDN
Eledon Pharmaceuticals Inc.
$2.60
+$0.05(+1.96%)
72
Overall
--
Value
72
Tech
--
Quality
Market Cap
$141.92M
Volume
1.10M
52W Range
$2.32 - $5.54
Target Price
$9.50
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-45.3M | $-5.1M | $-13.1M | $-14.1M | $14.2M | $18.5M | $36.9M | $39.8M | $43.0M | $70.6M | ||
| Research & Development | $32.6M | $3.2M | $2.0M | $6.8M | $8.1M | $6.1M | $23.7M | $27.1M | $30.3M | $52.0M | ||
| Research Expense | $32.6M | $3.2M | $2.0M | $6.8M | $8.1M | $6.1M | $23.7M | $27.1M | $30.3M | $52.0M | ||
| Selling, General & Administrative | $12.6M | $1.9M | $11.1M | $7.2M | $6.1M | $10.1M | $13.1M | $12.7M | $12.7M | $18.6M | ||
| General & Administrative Expenses | $12.6M | $1.9M | $11.1M | $7.2M | $6.1M | $10.1M | $13.1M | $12.7M | $12.7M | $18.6M | ||
| Salaries & Wages | $-2.9M | $-171.0K | $-579.0K | $-1.5M | $-1.3M | -- | -- | -- | $6.5M | $13.1M | ||
| Depreciation & Amortization | $-109.0K | $-171.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-109.0K | $-171.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | $48.6M | $48.6M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | $-75.0K | $-158.0K | $-214.0K | $-233.0K | $-712.0K | $-914.0K | $-972.0K | $-2.6M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-45.3M | $-5.1M | $-13.1M | $-14.1M | $-14.2M | $-18.5M | $-36.9M | $-88.4M | $-43.0M | $-70.6M | ||
| EBITDA | $-44.9M | $-5.6M | $-13.1M | $-14.1M | $-15.8M | $-16.0M | $-36.7M | $-39.4M | $-116.2M | $-35.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $174.0K | $164.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $174.0K | $164.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain on Sale of Securities | $-55.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $55.0K | $527.0K | $-5.0K | $5.0K | $-40.0K | $-79.0K | $-7.0K | $-48.2M | $-2.7M | $-3.9M | ||
| Other Special Charges | -- | $-527.0K | $5.0K | $-5.0K | $40.0K | $79.0K | $7.0K | $462.0K | $2.7M | $3.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-133.0K | $42.6M | $11.8M | -- | -- | $2.3M | $2.3M | -- | -- | -- | ||
| Special Income Charges | $133.0K | $-42.6M | $-11.8M | -- | $-1.9M | $-2.3M | $-2.3M | $-48.6M | -- | -- | ||
| Impairment of Capital Assets | -- | $-237.0K | -- | -- | $1.9M | -- | -- | $48.6M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-16.2M | $-36.9M | $-39.8M | $-116.5M | $-35.8M | ||
| Pre-Tax Income | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-23.2M | $-36.9M | $-88.0M | $-116.5M | $-35.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $-404.0K | $-1.9M | $-90.0K | $-38.0K | $-404.0K | $-2.4M | -- | -- | $431.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-22.8M | $-34.5M | $-88.0M | $-116.5M | $-36.2M | ||
| Net Income (Continuing Operations) | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-22.8M | $-34.5M | $-88.0M | $-116.5M | $-36.2M | ||
| Net Income (Discontinued Operations) | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-22.8M | $-34.5M | $-88.0M | $-116.5M | $-36.2M | ||
| Net Income (Common Stockholders) | $-45.1M | $-5.7M | $-13.1M | $-14.1M | $-16.0M | $-22.8M | $-34.5M | $-88.0M | $-116.5M | $-36.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-39.2M | -- | -- | $-35.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-45.3M | $-5.1M | $-13.1M | $-14.1M | $14.2M | $18.5M | $36.9M | $39.8M | $43.0M | $70.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.2M | $1.3M | $259.9K | $500.3K | $655.5K | $1.5M | $14.8M | $14.3M | $24.6M | $48.5M | ||
| Average Shares Outstanding (Diluted) | $1.2M | $1.3M | $316.8K | $500.9K | $655.5K | $1.5M | -- | $14.3M | $24.6M | $48.5M | ||
| Shares Outstanding | $139.7K | $139.8K | $522.6K | $524.1K | $892.8K | $14.3M | $14.3M | $13.8M | $24.8M | $59.9M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-15.72 | $-2.33 | $-6.16 | $-4.73 | $-0.75 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-15.72 | $-2.33 | $-6.16 | $-1.64 | $-0.75 | ||
| Diluted EPS | $-36.18 | $-30.24 | $-41.4 | $-28.08 | $-24.48 | $-15.72 | $-2.33 | $-6.16 | $-4.73 | $-0.75 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-24.48 | -- | -- | $-6.16 | $-1.64 | $-0.75 | ||
| OTHER METRICS | ||||||||||||
| Net Income From Other Gains Losses | $174.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $12.6M | $1.9M | $11.1M | $7.2M | $6.1M | $10.1M | $13.1M | $12.7M | $12.7M | $18.6M | ||
| Rent And Landing Fees | $12.6M | $1.9M | $11.1M | $7.2M | $-188.0K | $207.0K | -- | -- | -- | -- | ||
| Restruct | $-133.0K | $42.6M | $11.8M | -- | -- | $2.3M | $2.3M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELDN | $2.60 | +2.0% | 1.10M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Eledon Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW